IMS Health — Q4 2014 Earnings Presentation
22 slides from IMS Health's earnings presentation, Feb 3, 2015
Slide 1: IMS Health Q4 2014 Earnings Call
IMS Health Q4 2014 Earnings Call February 3, 2015 IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 2: Legal
Legal This presentation should be viewed in conjunction with IMS Health’s Q4 2014 earnings call Safe Harbor Statement This presentation includes “forward-looking statements”, including statements regarding future financial and operating results, especially those set forth under the heading “Full-Yea
Slide 3: 4th Quarter Results
4th Quarter Results $M Revenue EBITDA +6 2% +6.2% +8 5% +8.5% @ CFx @ CFx $678 $674 $214 $ $211 Q4 2014 Q4 2013 Q4 2014 Q4 2013 Note: Dollars are actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as defined in the IMS Health earnings release IMS Health Confidential
Slide 4: Cegedim Update
Cegedim Update Status Financials Works council information and Revenue consultation lt ti requirements i t 42% Information Cegedim Board of Directors approval 25% Other 33% Tech Svs Fully executed Definitive Purchase Agreement 2013 Financials ((1)) Revenue: $491M U.S. and Europe regulatory a
Slide 5: 4th Quarter Offering Revenue
4th Quarter Offering Revenue Offering 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Information $366 $387 0.8% (5.5%) Technology Services $312 $287 13.6% 8.8% Total $678 $674 6.2% 0.6% IMS Health Confidential. Do not distribute outside your organization. 5 (c) 2015 IMS Health
Slide 6: 4th Quarter Geographic Revenue
4th Quarter Geographic Revenue Geography 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Developed Markets $565 $560 5.5% 0.9% Emerging Markets $113 $114 9.7% (1.0%) Total $678 $674 6.2% 0.6% IMS Health Confidential. Do not distribute outside your organization. 6 (c) 2015 IMS H
Slide 7: 4th Quarter EBITDA
4th Quarter EBITDA 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Adjusted EBITDA (1) $214 $211 8.5% 1.1% Adjusted EBITDA 31.6% 31.4% 68 bps 18 bps margin g (1) See reconciliations of non-GAAP items in appendix IMS Health Confidential. Do not distribute outside your organizati
Slide 8: 4th Quarter P&L
4th Quarter P&L At reported FX rates $M (except per share data) 2014 2013 Net Income / (Loss) $8 $82 Diluted Earnings / (Loss) per Share $0.03 $0.29 Adjusted Net Income (1) $125 $79 Adjusted Diluted Earnings per Share (1) $0.36 $0.28 (1) See reconciliations of non-GAAP items in appendix IMS Health C
Slide 9: Full-Year Revenue
Full-Year Revenue Offering Full-Year Versus Prior Year Constant $M 2014 2013 Reported Currency Information $1,515 $1,525 1.7% (0.7%) Technology Services $1,126 $1,019 12.3% 10.6% Total $2,641 $2,544 5.9% 3.8% Geography Full-Year Versus Prior Year Developed Markets $2,181 $2,107 4.9% 3.5% Emerging Ma
Slide 10: Full-Year P&L
Full-Year P&L At reported FX rates $M (except per share data) 2014 2013 Adjusted EBITDA (1) $878 $829 Adj t d EBITDA margin Adjusted i 33 2% 33.2% 32 6% 32.6% Net Income / (Loss) $(189) $82 Diluted Earnings / (Loss) per Share $(0.59) $0.29 Adjusted Net Income (1) $454 $385 Adjusted Diluted Earnings
Slide 11: 4th Quarter Balance Sheet Items & Metrics
4th Quarter Balance Sheet Items & Metrics $M 2014 2013 Cash & Cash Equivalents & Short-Term $390 $729 (1) I Investments t t (3) Principal Balance of Debt (2) $3,816 $5,027 (1) Net Debt $3,426 $4,298 (1) Gross Leverage Ratio 4.3x 6.1x (1) Cash Provided by Operating Activities $147 $78 Capital Expendi
Slide 12: 2014 Foreign Currency Impact
2014 Foreign Currency Impact Core IMS Reported vs. constant currency (reported < constant currency), currency) reported > constant currency Growth rate FY 2014 Constant impact of FX Q1 Q2 Q3 Q4 FY Currency Growth Revenue (1.4)% 0.7% (1.7)% (5.6)% (2.1)% 5.9% Adjusted (2.3)% (0.1)% (4.4)% (7.4)% (3.6
Slide 13: 1st Quarter 2015 Foreign Currency Impact
1st Quarter 2015 Foreign Currency Impact Core IMS Reported vs. constant currency (1) (reported < constant currency), currency) reported > constant currency Growth rate impact of FX Q1 Revenue (8.4)% Adjusted (9.6)% EBITDA (1) Assuming current exchange rates remain unchanged to the end of the first q
Slide 14: Full-Year 2015 Guidance
Full-Year 2015 Guidance Core IMS IMS w/Acquisition (2) Constant Currency Constant Currency Reported (1) Revenue Growth 5 - 6% 19 - 20% 11 - 12% Adjusted EBITDA 7.5 - 8.5% 13 - 14% 5 - 6% Growth Adjusted Net Income Growth 16 - 19% 20 - 23% 8 - 11% Adjusted Diluted 11 - 14% 15 - 18% 4 - 6% EPS (1) A A
Slide 15: Q&A
Q&A IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 16: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 17: Net Income to Adjusted EBITDA
Net Income to Adjusted EBITDA Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Net Income (Loss) $ 8 $ 82 $ (189) $ 82 Provision for (benefit from) income taxes 45 (124) (96) (130) Other (income) loss, net(1) (5) 30 276 74 Interest expense 40 91 221
Slide 18: Net Income to Adjusted Net Income & Per Share Data
Net Income to Adjusted Net Income & Per Share Data Three Months Ended Twelve Months Ended December 31, December 31, (in millions, except per share data) 2014 2013 2014 2013 Net Income (Loss) $ 8 $ 82 $ (189) $ 82 Provision for (benefit from) income taxes 45 (124) (96) (130) Amortization associated w
Slide 19: Unlevered Free Cash Flow
Unlevered Free Cash Flow Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Net Cash (Used in) Provided by Operating $ 147 $ 78 $ 110 $ 414 A ti iti Activities Capital expenditures (13) (16) (72) (41) Additions to computer software (25) (28) (95) (81)
Slide 20: Gross Leverage Ratio
Gross Leverage Ratio December 31, 2014 (in millions) Gross Debt $ 3,816 Adj t d EBITDA (f Adjusted (for th the ttwelve l months th ended d d December D b 31, 31 2014) $ 878 Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.3x IMS Health Confidential. Do not distribute outside your organization
Slide 21: Non-GAAP Adjustments By Income Statement Line Items
Non-GAAP Adjustments By Income Statement Line Items Three Months Twelve Months Ended Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Non-GAAP adjustments included in: Operating costs of information, exclusive of 2 2 21 9 depreciation and amortization Direct and incremental costs of
Slide 22: END
END IMS Health Confidential. Do not distribute outside your organization. 22 (c) 2015 IMS Health Incorporated. All Rights Reserved.